A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical trial NCT03575819 · COMPLETED

Trial details

NCT number: NCT03575819
Sponsor: Fortis Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Prostate Cancer Metastatic

Start date: 2019-02-04
Primary completion: 2023-11-16
Enrollment: 56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.